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Chromosome 5q deletions (del[5q]) are common in
high-risk (HR) myelodysplastic syndrome (MDS) and
acute myeloid leukemia (AML); however, the gene
regulatory networks that sustain these aggressive
diseases are unknown. Reduced miR-146a expres-
sion in del(5q) HR MDS/AML and miR-146a/ he-
matopoietic stem/progenitor cells (HSPCs) results in
TRAF6/NF-kB activation. Increased survival and pro-
liferation of HSPCs frommiR-146alowHRMDS/AML is
sustained by a neighboring haploid gene, SQSTM1
(p62), expressed from the intact 5q allele. Overex-
pression of p62 from the intact allele occurs through
NF-kB-dependent feedforward signaling mediated
by miR-146a deficiency. p62 is necessary for
TRAF6-mediated NF-kB signaling, as disrupting the
p62-TRAF6 signaling complex results in cell-cycle ar-
rest and apoptosis of MDS/AML cells. Thus, del(5q)
HR MDS/AML employs an intrachromosomal gene
network involving loss of miR-146a and haploid over-
expression of p62 via NF-kB to sustain TRAF6/NF-kB
signaling for cell survival and proliferation. Interfering
with the p62-TRAF6 signaling complex represents a
therapeutic option in miR-146a-deficient and aggres-
sive del(5q) MDS/AML.
INTRODUCTION
Deletions involving the long arm of chromosome 5 (chr5), del(5q),
are the most common cytogenetic abnormalities in myelodys-
plastic syndrome (MDS) and secondary acute myeloid leukemia
(AML) (Ebert, 2009). 5q syndrome, a clinical entity defined by1328 Cell Reports 8, 1328–1338, September 11, 2014 ª2014 The Auan isolated del(5q) with a blast count of <5%, confers a favorable
prognosis and responsiveness to lenalidomide (Greenberg et al.,
2012; List et al., 2006). However, a large proportion of del(5q) pa-
tients have bone marrow (BM) blasts exceeding 5%, complex
cytogenetics, and extremely poor prognosis and are refractory
to available treatments (Giagounidis et al., 2006). Minimally
deleted regions (MDRs) have been mapped and extensively
studied (Ebert, 2009). The distal MDR (5q33.3) on chromosome
5q (chr5q) is associated with a favorable outcome, while the
proximal MDR (5q31.1) is associated with worse prognosis
and leukemic transformation. More recently, high-resolution
genomic analyses on an extensive patient cohort has added
new insight into the clinical and genomic correlates of del(5q)
myeloid malignancies. It was shown that the extent of the
deleted region on 5q determines clinical characteristics (Jerez
et al., 2012); that is, chr5q deletions extending beyond q34
portend a worse overall survival and are associated with high-
risk (HR) disease. One potential candidate on chr5q is miR-
146a, a microRNA (miRNA) implicated in del(5q) MDS/AML
pathogenesis, which resides on band q34. From previous
work, a subset of miR-146a/ mice develop MDS, a myeloid
proliferative disease, and/or myeloid tumors resembling AML,
in part by derepression of tumor necrosis factor receptor-asso-
ciated factor 6 (TRAF6) and persistent NF-kB activation (Boldin
et al., 2011; Starczynowski et al., 2010; Zhao et al., 2011,
2013). The mechanism accounting for the variable phenotype
and disease latency of miR-146a/ mice is still unresolved,
particularly as it relates to disease initiation versus diseasemain-
tenance. In addition, a small-molecule inhibitor of IRAK1 sup-
presses TRAF6 and NF-kB activation and induces apoptosis of
primary MDS-propagating cells but is less effective as a single
agent in primary AML (Rhyasen et al., 2013). Therefore, under-
standing the contribution of miR-146a deficiency to the main-
tenance of HR MDS/AML and uncovering novel therapeutic
opportunities is warranted.thors
Figure 1. miR-146a Deletion Mediates
HSPC Hyperproliferation
(A) Overexpressed genes from low miR-146a-ex-
pressing del(5q) MDS/AML patients and miR-
146a/ (KO) marrow cells were compared using
ToppGene.
(B and C) Cell-cycle analysis was performed on
LinSca-1+cKit+ (LSK) and SLAM+ cells from WT
(n = 4) and KO (n = 6) mice by Pyronin Y/Hoechst
33342 staining. Shown is a representative plot for
LSK (B) and summary for LSK and SLAM+ cells (C).
*p < 0.05.
(D) Annexin V staining was performed on LincKit+
cells from WT (n = 4) and KO (n = 6) mice.
See also Figure S1 and Table S1.RESULTS
Loss of miR-146a expression either by miRNA decoy or by ge-
netic deletion in mouse hematopoietic stem/progenitor cells
(HSPCs) results in features of 5q syndrome, fatalmyeloidmalig-
nancies, and altered hematopoietic proportions (Figures S1A–
S1F) (Boldin et al., 2011; Zhao et al., 2011, 2013); however, the
effects of miR-146a loss that explain the clinical findings and sus-
tained malignant cell growth in aggressive/HR del(5q) MDS/AML
are not known. To investigate a connection between miR-146a
loss and the cellular phenotype of del(5q) MDS/AML cells, gene
expression patterns and Gene Ontology (GO) categories using
ToppGene (Chen et al., 2009) were compared between HSPCs
from miR-146alow del(5q) MDS/AML patients (Table S1) and
miR-146a/ mice. The expression of miR-146a in this subset
of del(5q) MDS/AML patients, which is80% lower as compared
to age-matched controls, is best approximated by miR-146a/
mice for functional comparisons as miR-146a expression in
miR-146+/ (Het) BM cells is similar to wild-type (WT) mice (Fig-
ures S1A and S1G). The overlapping pathways were nearly iden-
tical between the two groups, which included overexpression of
cell cycle, innate immune response, and survival pathway genes
(Figure 1A). In support of the gene expression patterns, hemato-
poietic stem cells (HSCs) frommiR-146a/mice have increased
Pyronin Y (Figures 1B and 1C) and reduced Annexin V staining
(Figure 1D; p = 0.09), suggesting that miR-146a-deficient HSCs
are less quiescent and have increased survival. Consistent with
increased HSPC proliferation and survival, miR-146/ mice
exhibit myeloid expansion (increased CD11b+ cells as compared
to WT HSPCs; Figures S1D and S1E) and impaired competitive
engraftment (reduced CD45.2% chimerism in the peripheral
blood; Figure S1F). As reported previously (Boldin et al., 2011;
Starczynowski et al., 2010; Taganov et al., 2006), loss of miR-
146a in leukemic cells results in derepression of TRAF6, a medi-Cell Reports 8, 1328–1338, Sepator of NF-kB activation (Figures S1H–
S1K), implicating this molecular complex
in the aggressive nature of the del(5q)
MDS/AML phenotype.
Inhibiting the TRAF6/NF-kB axis may
represent a therapeutic opportunity for
aggressive forms of del(5q) MDS/AML
with low miR-146a expression. Unfortu-nately, the success of direct inhibitors of NF-kB for human can-
cers has yet to be proven. Chromosome deletions that target
tumor suppressor genes also involve multiple neighboring
genes, such as with del(5q), and loss of certain neighboring
genes may expose cancer-specific vulnerabilities and potential
therapeutic targets (Muller et al., 2012; Nijhawan et al., 2012).
To overcome the limitations of NF-kB inhibitors and identify
novel mechanisms of disease dependency, we examined the
expression of all genes residing within chr5q from del(5q) and
control CD34+ cells (Figure S2A). Of 1,528 chr5q genes, 374
genes were significantly lower (<0.5-fold) and 27 were higher
(e.g., overexpressed/restored from the intact allele >1.5-fold) in
del(5q) cells (Figure 2A; Table S2). We also examined the 27
overexpressed genes in non-del(5q) MDS (Figure S2B). Intere-
stingly, a subset of these genes were also overexpressed in
non-del(5q) MDS, but not to the same extent as in del(5q) MDS
(Figure S2C). In addition, we utilized GeneConnector function-
ality in NetWalker to build molecular networks (Figure S2A) (Ko-
murov et al., 2012). A single major ‘‘NF-kB’’ molecular node and
a minor node related to ‘‘coagulation response’’ formed corre-
sponding to the overexpressed chr5q genes (Figure 2B). To
determine whether the ‘‘NF-kB node’’ is important for the prolif-
erative phenotype in aggressive del(5q) MDS/AML, human
leukemic and normal CD34+ cells were treated with an NF-kB in-
hibitor (BAY 11-7085) and then analyzed for cell-cycle kinetics
and viability. Following treatment with BAY 11-7085 or by knock-
down of TRAF6, all MDS/AML cells exhibited a G2/M arrest and
apoptosis (Figures S2D–S2H). In addition, miR-146a/ HSPCs
were more sensitive to NF-kB pathway inhibition by BAY 11-
7085 thanWT HSPCs, as evident by enhanced G2/M arrest (Fig-
ure S2G) and apoptosis (Figure S2I). These findings indicate that
human and mouse miR-146alow HSPCs are sensitive to genetic
and pharmacologic inhibition of the TRAF6/NF-kB pathway,
suggesting an acquired dependency on TRAF6.tember 11, 2014 ª2014 The Authors 1329
Figure 2. Del(5q) MDS/AML Are Associated with an Intrachromosomal NF-kB Feedforward Gene Network
(A) Gene expression profiling of differentially expressed chr5q genes (q11–q35) in del(5q) MDS (n = 47) as compared to normal control CD34+ cells (n = 17).
(B) GeneConnector functionality in NetWalker was used to build a molecular network of genes that are overexpressed in del(5q) MDS (see Table S2 for all genes
used in the analysis). Red nodes indicate genes overexpressed in del(5q) MDS. Gray nodes indicate molecularly connected genes. Gray nodes with red stripes
indicate validated miR-146a gene targets. Dotted lines indicate the chromosome position of each gene.
(C and D) Enrichment scores for DNA binding motifs in the promoter regions of overexpressed 5q genes (C) and NF-kB node genes (D). Each point represents the
enrichment Z score for a single transcription factor (TF) bindingmotif. Enrichedmotifs for NF-kB are indicated with arrows, along with their overall rank among the
1,867 total human TF motifs analyzed. Horizontal dashed line indicates the (uncorrected) significance threshold corresponding to a p value cutoff of 0.01 (see
Table S3).
(E) Knockdown of SNCAIP,MAP3K1, PDLIM7, p62, TRAF6, and IRAK1 in HL60 cells was achieved by shRNAs. Solid red histograms represent genes within the
‘‘NF-kB node’’ that reside on chr5q. Hatched red histograms represent genes within the NF-kB node that do not reside on chr5q (see Figure 2B). Transduced
HL60 cells were evaluated for colony formation inmethylcellulose following knockdown of each indicated gene. Colonies were scored and normalized to a control
shRNA. p < 0.05 for HL60 cells transduced with shp62, shTRAF6, and shIRAK1.
See also Figure S2 and Tables S2 and S3.Given the paradoxical overexpression of genes from the intact
chr5 allele, we hypothesized that the 27 overexpressed genes
might be coregulated by a common transcription factor (TF).
We compiled a data set containing 1,867 DNA binding motifs
representing the binding preferences of 623 human TFs to
search for enriched TF binding sites in the promoter regions of
the 5q overexpressed genes (Zambelli et al., 2009). Of all TF mo-
tifs, NF-kB binding sites are the most strongly enriched in the
entire overexpressed/compensated gene set (Figure 2C; p =
0.0001) and even further enriched in the NF-kB node gene set
(Figure 2D; p = 0.0007) (Table S3). To further explore the broader
regulation of NF-kB-target gene expression, we examined two
canonical NF-kB gene targets in normal CD34+, del(5q) MDS,
and non-del(5q) MDS. Despite the enrichment of NF-kB binding
sites in a subset of genes residing on chr 5q, not all NF-kB-regu-
lated genes are overexpressed in del(5q) MDS (Figure S2C). To
determine which genes within the NF-kB node are necessary
for del(5q) leukemic cell function, we knocked down the expres-1330 Cell Reports 8, 1328–1338, September 11, 2014 ª2014 The Ausion of each gene and examined leukemic progenitor function
(Figure 2E). Based on previous reports, knockdown of TRAF6
or IRAK1 significantly impaired HL60 colony formation (Fig-
ure 2E). Of the genes within the NF-kB node that reside on
chr5q, only knockdown of sequestosome 1 (SQSTM1/p62) re-
sulted in reduced colony formation. Knockdown of the remaining
NF-kB node genes did not result in impaired leukemic progenitor
function, suggesting these genes are not sufficient to sustain
the NF-kB-mediated survival signal. Among the overexpressed
genes residing on chr5q and within the NF-kB node, p62
(5q35, p = 0.0054; adjusted p = 0.023) emerged as an obvious
candidate (Table S2), as it is required for leukemic progenitor
function and is a cofactor for NF-kB activation through recruit-
ment of TRAF6 (Duran et al., 2008; Linares et al., 2011; Moscat
and Diaz-Meco, 2009; Wooten et al., 2005).
miR-146a regulates several genes within the innate immune
pathway; however, an analysis of the 30 UTR of p62 did not reveal
miR-146a binding sites, suggesting an alternative mechanism ofthors
p62 overexpression in miR-146alow cells. Examination of the p62
promoter region using ENCODE functional genomics data
(Rosenbloom et al., 2013) revealed the presence of two NF-kB
(p50) chromatin immunoprecipitation sequencing (ChIP-seq)
binding peaks (kB site motif: NGGGACTTTCCN) (Chen et al.,
1998) in hematopoietic cells (Figure 3A). Both NF-kBbindingmo-
tifs directly overlap DNase I-hypersensitive, H3K4mono- and tri-
methylation, and H3K27 acetylation regions in hematopoietic/
leukemic cells, reaffirming the prediction analysis (Figure 2)
and confirming that NF-kB also binds these regions in leukemic
cells. Therefore, these analyses suggest that NF-kB transcription
factors regulate a subset of overexpressed genes on chr5q, one
of which (p62) is a signaling mediator of the canonical NF-kB
pathway. Analysis of an independent cohort of patients revealed
that p62 expression inversely correlated with miR-146a expres-
sion in HR del(5q) MDS/AML (p = 0.013; Figure 3B). Consistent
with RNA expression in primary MDS/AML cells, p62 protein is
expressed at normal or even at elevated levels despite deletion
of one p62 locus in certain MDS/AML samples and cell lines (Fig-
ure 3C; Figure S3). To further examine the molecular relationship
among miR-146a, NF-kB, and p62, additional knockdown of
miR-146a resulted in elevated p62 expression following inter-
leukin-1b (IL-1b)-mediated (TRAF6-dependent) NF-kB activa-
tion, but not with tumor necrosis factor a stimulation (TRAF6
independent) (Figure 3D). Similarly, miR-146a/ marrow cells
exhibit elevated p62mRNA and protein expression following IL-
1b-induced NF-kB activation (Figures 3E and 3F). We sought to
investigate whether compensation of p62 in this subset of
del(5q) MDS/AML modified clinical outcome. Del(5q) MDS/AML
patients were divided into miR-146alow/p62high and miR-
146ahigh/p62low cohorts. Based on this stratification, del(5q)
MDS/AML with miR-146alow/p62high had a significantly worse
overall survival (Figure 3G; p = 0.0064), further implicating p62
as an essential cofactor in aggressive formsof del(5q)MDS/AML.
We next determined the function of p62 in miR-146alow-ex-
pressing HSPCs. Overexpression of p62 in miR-146a/ HSPCs
further increased cell proliferation as the proportion of cells in S
phase increased and the proportion in G2/M decreased,
whereas overexpression of p62 did not affect WT HSPCs (Fig-
ure 3H). Conversely, knockdown of p62 in miR-146a/ HSPCs
(Figure 3I) reversed the proliferative phenotype by arresting cells
in G2/M (Figures 3J and 3K). However, knockdown of p62 in
WT HSPCs resulted in minor changes in cell-cycle progression
(Figures 3J and 3K). Since transplantation of miR-146a/ BM
results in diminished competitive myeloid reconstitution in recip-
ient mice (Figure S1F), we evaluated whether knockdown of p62
can restore these cellular consequences. As expected, knock-
down of p62 in WT HSPC did not alter proportions of CD11b+
or CD3+ cells, while transplantation of miR-146a/ HSPCs
transduced with control small hairpin RNA (shCTL) resulted in
diminished myeloid reconstitution in recipient mice (Figure 3L).
In contrast, knockdown of p62 in miR-146a/ HSPCs restored
normal proportions of CD11b+ cells (Figure 3L; p = 0.04). There-
fore, p62 is essential in miR-146alow-expressing premalignant
mouse HSPCs by regulating cell-cycle progression and myeloid
cell development.
p62 is essential in certain solid tumors (Duran et al., 2008; Ling
et al., 2012); therefore, we investigated whether p62 serves aCell Resimilarly essential role in human myeloid malignancies. Utilizing
lentiviral vectors encoding small hairpin RNAs (shRNAs) target-
ing p62 (Figure S4A), knockdown of p62 significantly reduced
TRAF6 activation by75%, asmeasured by K63-linked autoubi-
quitination, in two human del(5q) MDS/AML cell lines (Starczy-
nowski et al., 2011) (Figure 4A). Knockdown of p62 also resulted
in impaired NF-kB/p65 nuclear localization, but only following
loss of miR-146a (Figure 4B). To examine the effects of p62
depletion in vivo, the MDS/AML cell lines were transduced with
shp62 or control (shCTL) and then xenografted into nonobese
diabetic scid gamma (NSG) mice. By 6–7 weeks, control
leukemic cells expanded 8-fold in the peripheral blood, while
leukemic cells with p62 knockdown did not expand and re-
mained below 10% chimerism (Figure 4C). Mice with HL60 or
MDS-derived cell line (MDSL) xenografts expressing shCTL suc-
cumbed to leukemic cell burden by 7 and 10 weeks, respectively
(Figures 4C and 4D; Figure S4B). In contrast, p62 knockdown
prevented expansion of engrafted leukemic cells and signifi-
cantly delayed mortality in mice (Figures 4C and 4D). To investi-
gate the cellular effects of p62 depletion in vitro, miR-146alow
MDS/AML cell lines and primary del(5q) AML samples were
examined for progenitor function, survival, and proliferation. All
MDS/AML cell lines with knockdown of p62 exhibited >80%
reduction of leukemic progenitor colonies in methylcellulose
(p < 0.05 for all) (Figures S4C and S4D). In addition, p62 regulates
leukemic cell proliferation, as knockdown of p62 resulted in de-
layed growth in vitro, fewer cells in S phase, and accumulation of
G0/G1 and G2/M cells (Figure S4E). MDS/AML cell lines with
knockdown of p62 correlated with a significant increase in
apoptosis (increased Annexin V+ cells; Figure 4E). Loss of p62
did not coincide with a significant increase in apoptosis or
changes in cell cycle of control CD34+ cells (Figures 4E–4G),
suggesting that malignant HSPCs are more sensitive to p62 inhi-
bition. For primary del(5q) MDS/AML cells, knockdown of p62
also resulted in increased apoptosis (increased Annexin V+ cells;
Figure 4F; Figure S4F) and suppression of cell cycle (Figure 4G).
Despite the differential sensitivity of normal and leukemic cells
to p62 knockdown, treatment with BAY 11-7085 induced
apoptosis in both cell types (Figure 4F), revealing that broadly in-
hibiting NF-kB results in cytotoxicity of normal cells, and as such,
the therapeutic limitations of NF-kB inhibitors. Given the role of
p62 in regulating autophagy in certain cell types, we examined
autophagy in leukemic cells. Notably, knockdown or overex-
pression of p62 did not change the autophagy status in leukemic
cells (Figure S4G).
The p62 signaling domains have been extensively mapped
(Moscat and Diaz-Meco, 2009) (Figure 5A). For NF-kB signaling,
p62 recruits and activates TRAF6 via its TRAF6-binding (TB)
domain (amino acids 228–242), which then results in signaling
to IkB kinase (IKK) a/b and NF-kB (Figure 5A) (Seibenhener
et al., 2004; Wooten et al., 2005). To determine whether TRAF6
recruitment is essential for p62 function in MDS/AML cells, WT
p62 or a mutant p62 lacking the TB domain (p62DTB) was coex-
pressed with shp62. Cell viability was restored in shp62-ex-
pressing cells when WT p62 was expressed, but not p62DTB,
suggesting that interaction with TRAF6 is essential for the effects
of p62 in leukemic cells (Figures 5B and 5C). We hypothesized
that interfering with the p62-TRAF6 signaling complex inports 8, 1328–1338, September 11, 2014 ª2014 The Authors 1331
Figure 3. p62 Is Overexpressed through NF-kB Activation and Is an Essential Cofactor in miR-146a/ HSPCs
(A) Schematic of the p62 (SQSTM1) promoter region. UCSC Genome Browser image displays ENCODE consortium data indicating (top to bottom): location of
SQSTM1 gene (exons depicted as filled boxes, introns as lines with arrows); location of two NF-kB binding regions, based on ChIP-seq data in B cell lines;
location of DNase I-hypersensitive regions (indicative of open chromatin) in HL60 andNB4 cells; various histonemarks (all indicative of regulatory regions) in K562
cells.
(B) p62 expression in AML marrow cells with high (top 50th percentile) or low (bottom 50th percentile) miR-146a.
(C) Immunoblot analysis of p62 in del(5q) AML/MDS patient BM cells and normal CD34+ cells. The miR-146a and p62 locus status is indicated below (N, normal
diploid; hap, haploid).
(D) qRT-PCR expression of p62 in TF1 leukemic cells transduced with vector or miR-146 decoy and then treated with IL-1b or tumor necrosis factor a.
(E) Quantitative RT-PCR (qRT-PCR) expression of p62 in HSPC from WT and miR-146/ mice after treatment with IL-1b at indicated time points.
(F) p62 immunoblot analysis on marrow cells from WT and miR-146/ mice after treated with IL-1b at indicated time points.
(G) Del(5q) MDS/AML patients were stratified into miR-146ahigh/p62low and miR-146alow/p62high RNA expression. Overall survival for del(5q) MDS/AML patients
based on high miR-146a/low p62 (green, n = 17) and low miR-146a/high p62 (red, n = 8).
(H) Cell-cycle analysis of WT and miR-146a/ BM transduced with vector (MSCV-IRES-GFP; MIG) or p62.
(I) Validation of p62 knockdown in WT and miR-146a/ BM cells by qRT-PCR.
(legend continued on next page)
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leukemic cells would be sufficient to inhibit TRAF6-mediated
activation of NF-kB and induce cell death and cell-cycle arrest.
The TB domain, which consists of 15 amino acids, was fused
to a hemagglutinin (HA) epitope tag and then cloned into a retro-
viral expression vector for sustained expression in leukemic
cells. A stop codon (TGA) was inserted following the last amino
acid (Lys-242). As a negative control, two critical residues
(Phe-232 and Glu-234) were changed to alanine (Figure 5A).
Expression of WT (TBWT) and control (i.e., inactive mutant:
TBMUT) TB peptide was confirmed by dot blot immunoassay in
transduced HL60 and transfected human embryonic kidney
293 (HEK293) cells (Figure 5D). To verify that the WT TB peptide
inhibits p62-mediated activation of TRAF6 (as measured by
K63-linked autoubiquitination), FLAG-TRAF6 and p62 were
cotransfected with TBWT or TBMUT into HEK293 cells followed
by immunoprecipitation of TRAF6. TRAF6 autoubiquitination
(immunoprecipitation: FLAG; immunoblotting: Ub) was in-
creased following cotransfection of p62, but was then signifi-
cantly reduced in cells expressing TBWT (Figure 5E). TBWT also
suppressed downstream NF-kB signaling as evident by 25%
reduced kB-site reporter gene activation (Figure 5F). To examine
themolecular and cellular effects of the TBWT peptide in disease-
relevant cells, we transduced HL60 cells with TBWT- and TBMUT-
expressing vectors (Figure 5D). Examination of NF-kB activation
showed less phosphorylated IKKa/b in TBWT-expressing HL60
cells (Figure 5G). Consistent with suppression of NF-kB/IKK acti-
vation, immunoprecipitation of TRAF6 from TBWT-expressing
HL60 cells revealed a 50% reduction in ubiquitinated TRAF6,
as compared to control (TBMUT) (Figure 5H). Inhibition of
TRAF6/NF-kB with TBWT in HL60 cells coincided with impaired
G2/M exit (Figure 5I; 26.8% versus 15.2%), apoptosis (Figure 5J;
16.2% versus 3.7%), and impaired leukemic progenitor function
(Figure 5K; 144 versus 307 colonies; p = 0.001), as compared to
normal CD34+ cells. These findings are consistent with the
cellular effects observed after depleting p62 (Figures 4E–4G;
Figures S4C–S4F). Importantly, TBWT expression also resulted
in apoptosis of three independent del(5q) AML patient-derived
cells but had no noticeable effect on normal CD34+ cells (Figures
5J–5L). Thus, the TBWTmotif exerts antileukemic effects by inter-
fering with TRAF6 and p62 signaling and resulting in cell-cycle
arrest, impaired leukemic progenitor function, and increased
apoptosis.
DISCUSSION
Several haploinsufficient genes have been identified and veri-
fied in the pathogenesis of del(5q) MDS/AML (Ebert, 2009).
Despite the progress, our knowledge of genes and gene net-
works that are necessary for sustaining the del(5q) MDS/
AML-propagating cells is insufficiently described. In this study,
we show that deletion of miR-146a in del(5q) MDS/AML cells
is associated with sustaining the disease phenotype by
increasing cell survival and proliferation of the propagating cells(J and K) Cell-cycle analysis of WT and miR-146a/ BM transduced with shCTL
(L) WT and miR-146a/HSPCs (CD45.2) transduced with shCTL or shp62 were m
irradiated recipients (n = 8/group). Myeloid and lymphoid proportions in the bloo
*p < 0.05; #p < 0.1. See also Figure S3.
Cell Rethrough the TRAF6/p62/NF-kB complex. TRAF6 signaling is
implicated in del(5q) myeloid malignancies (Starczynowski
et al., 2010; Zhao et al., 2013) and an important target in low-
risk (LR) MDS (Rhyasen et al., 2013); however, this study un-
covers the mechanism by which del(5q) cells have acquired
and sustained their dependency on the NF-kB network in HR
MDS patients (with elevated blasts) and AML. As part of our
effort to uncover del(5q) MDS/AML-specific vulnerabilities and
potential therapeutic targets, we identified a subset of 5q genes
in which their expression is restored from the intact 5q allele
and form an NF-kB signaling node in del(5q) MDS/AML.
Furthermore, a detailed promoter analysis confirmed enrich-
ment of NF-kB binding motifs within the promoters of the over-
expressed NF-kB node genes, suggesting that an NF-kB
feedforward loop exists and may be necessary to sustain the
NF-kB signaling pathway following deletion of miR-146a in
MDS/AML. p62, a key gene within the NF-kB signaling node
and an important signaling mediator of TRAF6, is expressed
from the intact allele, forming an intrachromosomal gene
network with miR-146a to regulate TRAF6 and NF-kB activation
(Figure 5M). Importantly, depletion of p62 has minimal effects
on survival, proliferation, or function of normal HSPCs.
Although our focus was on p62, we predict that the remaining
genes within the NF-kB node are also important for sustaining
NF-kB activation (Figure 2). NF-kB is one of the major pathways
regulated by activation of TRAF6; however, additional critical
pathways regulated by TRAF6 in LR MDS and HR MDS/AML
may be different, particularly as they relate to disease initiation
versus maintenance. Further investigation into deciphering
these molecular pathways during disease evolution and within
distinct MDS/AML subtypes is warranted.
Mouse genetic studies have shown that p62 regulates several
cellular functions, including bone remodeling, metabolism, and
cancer (Linares et al., 2013; Moscat and Diaz-Meco, 2009; Sei-
benhener et al., 2013). p62 protein contains five signaling and/
or interaction modules, including PB1, ZZ-type zinc finger
domain (ZZ), TRAF6-binding (TB) domain, LC3-interacting re-
gion (LIR), and ubiquitin-associated domain (UBA) (Figure 5A)
(Moscat and Diaz-Meco, 2009). Through the TB domain, p62
facilitates K63-linked polyubiquitination of TRAF6 and conse-
quently initiates NF-kB signaling (Sanz et al., 2000). Although
the TB domain of p62 has been shown to directly bind TRAF6,
overexpression of the TB peptide does not appear to be suffi-
cient to disrupt this interaction in leukemic cells despite effi-
ciently inhibiting p62/TRAF6/NF-kB signaling activity. In our
findings, the TB peptide inhibits TRAF6 activation (as measured
by TRAF6 autoubiquitination; Figures 5E and 5H) and signaling to
NF-kB (Figures 5F and 5G). Collectively, these observations sug-
gest that the TB peptide inhibits p62-mediated activation of
TRAF6; however, the mechanism by which TB peptide inhibits
TRAF6/NF-kB does not exclusively depend on disrupting the
TRAF6-p62 interaction. Nevertheless, we show that the TB pep-
tide exerts antileukemic effects by interfering with TRAF6 andor shp62 (J) and summary of replicate experiments (K).
ixed with 13 105 WT (CD45.1) marrow cells and then transplanted into lethally
d were analyzed 4 weeks posttransplantation.
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Figure 4. p62 Is Necessary for MDS/AML Cell Survival and Cell Proliferation
(A) p62 knockdown was confirmed by immunoblotting lysates isolated from cells expressing a control or shp62 lentiviral vector. TRAF6 ubiquitination was
measured following transduction with shCTL or shp62.
(B) TF1 cells cotransduced with the indicated vectors were examined for p65 DNA binding.
(C) HL60 cells transduced with shCTL or shp62 were engrafted into NSG mice (n = 5–8/group) and monitored for chimerism at the indicated time points.
(D) Survival curves for mice receiving shCTL- or shp62-transduced HL60 (top) or MDSL (bottom) cells.
(E) Annexin V staining of the indicated cells was determined following transduction with shCTL or shp62.
(F) Annexin V staining of control CD34+ and two del(5q) AML patient samples (PT-01 and PT-02) was determined following transduction with shCTL or shp62. As a
positive control, treatment with an NF-kB inhibitor (BAY, BAY 11-7085) resulted in nonspecific cell death.
(G) Cell-cycle analysis of CD34+ and two patient samples (PT-01 and PT-02) transduced with shCTL or shp62 was determined by Hoechst 33342 incorporation.
*p < 0.05. See also Figure S4.
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Figure 5. p62 Sustains NF-kB Activation and Leukemic Cell Function via Its TRAF6-Binding Domain
(A) Schematic of the p62 protein and its domains: PB1, ZZ-type zinc finger domain (ZZ), a TRAF6-binding (TB) domain, and LC3-interacting region (LIR), and a
ubiquitin-associated domain (UBA). The amino acid sequence of the TB domain and the schematic of a WT and mutant TB constructs are shown below.
(B and C) HL60 expressing MIG, MIG-p62, or MIG-p62DTB retroviral vectors were transduced with shCTL or shp62. p62 expression (B) and cell survival (C) was
analyzed 4 days posttransduction.
(D) Expression of empty vector (MSCV-pGK-GFP), TBMut, or TBWT by transient transfection in HEK293 or by transduction in HL60 was confirmed by dot blot
immunoassay.
(E) HEK293 cells transfected with the indicated constructs were analyzed by coimmunoprecipitation and immunoblotting.
(F) NF-kB activation was measured in HEK293 cells transfected with a kB site-luciferase and the indicated vectors (n = 3/group). Values represent kB-site firefly
over Renilla luciferase.
(G) IKKa/b phosphorylation was measured in HL60 cells transduced with TBMut or TBWT by immunoblotting.
(legend continued on next page)
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p62 signaling and resulting in cell-cycle arrest, impaired
leukemic progenitor function, and increased apoptosis. An
essential role of p62 in cancer-associated TRAF6/NF-kB has
been also described in solid tumors (Beg et al., 1995; Duran
et al., 2008). In one of these studies, p62 is required for RAS to
activate IKK through polyubiquitination of TRAF6 in lung adeno-
carcinomas. In normal and RAS-transformed cells, p62 controls
timely transit of cells through mitosis and tumor cell proliferation
(Linares et al., 2011). These previous findings are consistent with
our observation that p62 is important for increased cell prolifer-
ation and G2/M transition in miR-146alow-expressing leukemic
cells. Selectively inhibiting TRAF6 has not been feasible, as it
does not possess druggable protein interfaces; therefore, inter-
fering with the p62-TRAF6 interactionmay be a novel therapeutic
option, particularly in miR-146alow-expressing leukemia. Similar
approaches using a deliverable peptide to prevent protein inter-
actions have been proposed and successfully implemented in
human cancer (Thundimadathil, 2012).
Since del(5q) MDS/AML is associated with a variety of other
cytogenetic changes, for this study we focused on differentially
expressed genes residing within chr5. A focused analysis exam-
ining just chr5q genes allowed for a simpler interpretation while
providing a proof of concept that intra- and/or interchromosomal
gene networks may expose therapeutic vulnerabilities. Two
recent studies have proposed that passenger deletions, which
in certain cancers involve functionally redundant gene families
or necessary housekeeping genes, create therapeutic vulnera-
bilities (Muller et al., 2012; Nijhawan et al., 2012). This concept
is exemplified by the restored expression of p62 from the intact
chr5q allele in order to sustain NF-kB signaling by recruiting
TRAF6 in miR-146a-deficient HSPCs (Figure 5M). Del(5q)
MDS/AML patients with low miR-146a expression nearly always
have normal/elevated p62, highlighting the pathologic connec-
tion between miR-146a and p62. In addition, this study rein-
forces synthetic dependencies based on intrachromosomal
gene networks associated with a specific genomic alteration.
Although our findings revealed an important role of p62 in sus-
taining NF-kB-mediated proliferation and survival pathways in
HR del(5q) MDS/AML, based on p62 knockdown experiments,
we also anticipate that p62 will similarly sustain NF-kB signaling
in non-del(5q) AML cells with low miR-146a expression. Not all
NF-kB-target genes are overexpressed in del(5q) MDS as one
might have expected following deletion of miR-146a (Fig-
ure S2C). This observation suggests that there is selective regu-
lation of certain NF-kB-target genes, such as the ones described
as part of the intrachromosomal network within chr5 (Figures 2A(H) TRAF6 ubiquitination (TRAF6 immunoprecipitaion; Ub immunoblotting) was m
(I) Cell-cycle analysis of HL60 and CD34+ cells transduced with TBMut or TBWT w
(J) Annexin V staining of HL60 and control CD34+ cells was determined following
(K) HL60 and CD34+ cells were transduced with TBMut or TBWT and then plated i
scored 10–14 days after plating.
(L) Annexin V staining of control CD34+ cells and MDS/AML patient samples (PT
TBWT.
(M) Model of an intrachromosomal network involving miR-146a/p62/TRAF6/NF-k
protein. TRAF6 overexpression results in its autoubiquitination (green circles), w
NF-kB transcription factors induce p62/SQSTM1 expression from the remaining
through its TRAF6-binding domain (TB). The p62/TRAF6 signaling complex and
*p < 0.05.
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equally contribute to the del(5q) network and that intra- and inter-
chromosomal gene networks may expose therapeutic vulnera-
bilities in MDS/AML with other cytogenetic alterations (i.e.,
monosomy 7).
EXPERIMENTAL PROCEDURES
See Supplemental Experimental Procedures for additional information.
Mice and Primary Murine Bone Marrow Cell Culture
Animals were bred and housed in the Association for Assessment and Accred-
itation of Laboratory Animal Care-accredited animal facility of Cincinnati Chil-
dren’s Hospital Medical Center. Whole-body miR-146a/ mice were a kind
gift from Dr. Dinesh Rao (University of California, Los Angeles). All experiments
were carried out under approved animal protocols by the Cincinnati Children’s
Hospital Institutional Animal Committee. BM cells were obtained by crushing
the femur, tibia, and pelvic bone into RPMI 1640 containing 2% bovine serum,
1% penicillin-streptomycin, and 1 mM EDTA and then filtered through a 40 mm
cell strainer. The cells were maintained in RPMI 1640 supplemented with 10%
fetal bovine serum, 1% penicillin-streptomycin, recombinant mouse stem cell
factor (rmSCF; 02931, STEMCELL Technologies), mouse interleukin 3 (rmIL-3;
02903, STEMCELL Technologies), and human interleukin 6 (rhIL-6; 02606,
STEMCELL Technologies) at 10 ng/ml.
Patient Samples
Informed consent was obtained according to protocols approved by the re-
view boards of Cleveland Clinics. Diagnoses were reviewed at Cleveland
Clinics and adapted, when required, to World Health Organization 2008
criteria. For quantitative RT-PCR analysis, bone marrow aspirates were
collected from 41 patients and 15 age-matched healthy controls (Table S1).
For functional studies, MDS/AML peripheral mononuclear cells (Table S1)
were cultured in StemSpan serum-free expansion media (SFEM; STEMCELL
Technologies) supplemented with 100 ng/ml recombinant human stem cell
factor (rhSCF; 02830, STEMCELL Technologies), human Flt3 ligand (rhFL;
02840, STEMCELL Technologies), and human thrombopoietin (rhTPO;
02522, PeproTech) for 48 hr before transduction. Cells were cultured in rhSCF,
rhFlt3L, rhTPO, rhIL-3, and rhIL-6 at 10 ng/ml.
Transcription Factor Bioinformatic Analysis
To identify TFs that might be regulating the compensated genes on chr5q, we
searched for enriched TF binding motifs in their promoter regions. For each
gene, we defined the promoter region as the 1,000 bases upstream of the start
of the longest gene transcript, as annotated in the RefSeq database (Pruitt
et al., 2009). We compiled a total of 1,867 TF binding motif models (in the
form of position weight matrices) from Transfac (Matys et al., 2006), JASPAR
(Portales-Casamar et al., 2010), FactorBook (Wang et al., 2013), UniProbe (Ro-
basky and Bulyk, 2011), hmCHIP (Chen et al., 2011), and Jolma (Jolma et al.,
2013), which in total cover 623 distinct human TFs. We then used the Pscan
software package (Zambelli et al., 2009) to rank all TF motifs based on their
enrichment in the chr5q gene set, as compared to random expectation based
on background distributions obtained by scanning all RefSeq promoters.easured in HL60 transduced with TBMut and TBWT.
as determined by Hoechst 33342 incorporation.
transduction with TBMut or TBWT.
n methylcellulose for progenitor colony formation (n = 3/group). Colonies were
-01, PT-02, and PT-03) was determined following transduction with TBMut or
B in HR del(5q) MDS/AML. miR-146a deletion results in derepression of TRAF6
hich serves to recruit and then activate the NF-kB kinase complex (IKKa/b).
allele within del(5q). p62 is an important cofactor to sustain NF-kB activation
subsequent NF-kB activation can be inhibited by expressing the TB motif.
thors
Statistical Analysis
Results are depicted as the mean ± SEM. Statistical analyses were performed
using Student’s t test. For microarray data, Benjamini Hochberg correction
was applied based on the total number of gene expression probes analyzed
for the region. Probes with an adjusted p value% 0.05 were considered signif-
icant (Table S2). GraphPad Prism (v5, GraphPad) was used for statistical
analysis.ACCESSION NUMBERS
The GEO accession number for the microarray data reported in this paper is
GSE60649.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
four figures, and three tables and can be found with this article online at
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